Quantcast

Janssen nets FDA’s Breakthrough Therapy Designation for investigational prophylactic vaccine for the prevention of respiratory syncytial virus in older adults

The Janssen Pharmaceutical Companies of Johnson & Johnson got the FDA’s Breakthrough Therapy Designation for its investigational prophylactic vaccine for the prevention of #respiratory syncytial virus (RSV)- mediated lower respiratory tract disease in adults aged 60 years or older. @JNJNews

Read more